Leuka was founded in 1982 by one of the late Professor John Goldman patients, Lester Cazin, whose dying wish was to find a cure for leukaemia by funding research.
Goldman, Leuka's founding chairman, was a pioneer in bone marrow transplantation for Chronic Myeloid Leukaemia (CML) who wanted to see the latest research breakthroughs brought from
bench to bedside as quickly as possible.
Today, we continue in his footsteps and we
lead the way in curing leukaemia and turning scientific advances into clinical
care for over 30 years.
Founder Professor John Goldman’s leukaemia breakthrough
Professor John Goldman was a towering
figure in haematology, who developed ground-breaking effective treatments for
patients with leukaemia. His therapies transformed the outcome of hundreds of
thousands of patients with blood cancers across the world. Indeed, he was
pivotal in one of the great triumphs of modern cancer research – the use of a
molecular targeted drug for the treatment of Chronic Myeloid Leukaemia.
This drug transformed it from a typically fatal diagnosis to a manageable
Flagship treatment facilities
In 1998, with the help from the Lord Mayor
of London’s capital appeal, Leuka funded the building of a £10 million
flagship facility for leukaemia research and treatment. The Catherine Lewis Centre was named in recognition of Catherine, a
former patient of Professor Goldman, until her untimely death from leukaemia. Catherine’s father, David Lewis, is a trustee of Leuka.
Empowering the scientific research leaders of tomorrow
Excellent facilities must have world-class researchers, and as a charity we are committed to nurturing the next generation of clinical and scientific talent. In 2015 we introduced The John Goldman Fellowships for Future Science, funding the most exceptional scientists nationally, and bringing the most promising research to fruition.
Achieving a future free of leukaemia
We continue to look forward and use our resources wisely in our aim curing leukaemia and other blood cancers. In 2016 we became founding partners of the IMPACT partnership, a major new UK clinical trials platform for stem cell transplantation. Leuka has invested £1 million into the project alongside charity partners Anthony Nolan and NHS BT.
While match rates for potential stem cell donors have increased, more than 50% of patients who undergo a transplant either suffer complications or, sadly, die. This clinical trials project aims to have a clearer understanding of the causes of transplant failure, and we are proud to be part of this vital research.